Company Overview
X4 Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of novel therapeutics designed to treat rare diseases affecting the immune system. The company functions within the healthcare sector, specifically the biotechnology industry, where its primary focus is on advancing scientific solutions for complex medical conditions. With a market capitalization of $374.59M and annual revenue of $35.11M, the firm represents a mid-sized capitalization entity within the biotech landscape, though specific employee headcount data is currently unavailable. These financial figures indicate that the company is in a growth phase, generating revenue that supports high-value research initiatives while maintaining a market valuation that reflects potential future commercialization of its pipeline assets.
Financial Health
The company reported revenue of $35.11M for the trailing twelve months, yet this figure stands in stark contrast to a net income of $-79,199,000 and an EBITDA of $-78,606,000. This significant gap between positive revenue and substantial negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs inherent to the biotechnology sector. Additionally, the free cash flow stands at $-57,361,376, which indicates that the company is currently burning cash to fund its operations and pipeline advancement rather than generating positive cash flow from current activities. The gross margin is reported at 83.6%, suggesting that the core products or services retain a high percentage of revenue as gross profit before operating expenses are deducted. Conversely, the operating margin is -930.6% and the profit margin is -225.6%, both of which indicate that the company's operating expenses far exceed its revenue generation, a common characteristic of early-stage biopharmaceutical firms before product launch or profitability. On the balance sheet, the company holds $253.00M in cash against $77.28M in debt, with a debt-to-equity ratio of 41.49, suggesting a leveraged position where debt is present but significantly outweighed by available liquidity. The current ratio is 10.16, which indicates a very strong short-term liquidity position with current assets far exceeding current liabilities. Finally, the return on equity is -76.0% and the return on assets is -22.9%, revealing that management effectiveness is currently measured by the erosion of equity and assets due to operational losses rather than the generation of returns.
Valuation Assessment
The P/E ratio (TTM) is listed as N/A due to negative earnings, while the forward P/E is -4.46, implying that the market expects earnings to remain negative or that the current valuation is based on revenue multiples and other non-earnings metrics. The price-to-book ratio is 2.01, which indicates that the market is valuing the company at twice its book value, suggesting a premium assigned to its intangible assets, intellectual property, and future commercial potential. The price-to-sales ratio is 10.67 and the EV/EBITDA is -2.71, metrics that suggest the company is being valued primarily on its revenue generation capabilities rather than profitability, a standard practice for unprofitable biotech firms. The 52-week high is $9.30 and the 52-week low is $1.35, meaning the stock has experienced significant volatility within this trading range over the past year. The beta value is 0.46, which indicates that the stock's price volatility is less than that of the broader market, suggesting it moves with lower sensitivity to general market fluctuations.
Growth & Income
The revenue growth year-over-year is 79.1%, while earnings growth is N/A due to the absence of positive earnings, indicating that the company is expanding its top line rapidly but has not yet achieved profitability. Since the earnings growth rate is N/A, it implies that the company is reinvesting all available resources into research and development rather than distributing profits to shareholders. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not pay dividends and instead retains all earnings to fund its growth initiatives and operational needs. The overall growth and income profile is defined by rapid revenue expansion of 79.1% paired with a total absence of dividend distributions, reflecting a classic growth-stage biotechnology business model focused on pipeline development.